Arbaclofen placarbil: Completed Phase IIb enrollment

XenoPort disclosed in its 3Q10 earnings that it completed enrollment of 425 patients in a double-blind, placebo-controlled, North American Phase IIb trial evaluating arbaclofen placarbil at doses of 2...